Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
deals
7
×
life sciences
national blog main
boston top stories
clinical trials
fda
national top stories
boston
san francisco blog main
amgen
investing
roche
san francisco top stories
alexion pharmaceuticals
alnylam pharmaceuticals
boehringer ingelheim
cancer
cancer drugs
eli lilly
hepatitis b
new york blog main
new york top stories
novartis
rna interference
sanofi
the column group
abbvie
akouos
alirocumab
allergan aesthetics
alzheimer's disease
amyotrophic lateral sclerosis (als)
astellas pharmaceuticals
astrazeneca
athira pharma
attralus
autoimmune disorders
avapritinib
What
drug
7
×
medicines
fda
cancer
candidate
deal
disease
ipo
pharma
pharmaceuticals
research
roche
team
acquire
acquisitions
affects
agreed
alternative
americans
approval
approved
autoimmune
biggest
billion
bio
blueprint
brings
build
buy
cash
caught
causing
ceo
cholesterol
company
company’s
compound
currently
daniel
date
Language
unset
7
×
Current search:
biotech
×
deals
×
drug
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds